International consensus recommendations for identifying the optimal lenalidomide starting dose (when used in combination with dexamethasone) in patients with relapsed or refractory multiple myeloma, according to baseline renal function and cytopenia [21]. Each lenalidomide cycle is 21 days out of 28 days. Reproduced with permission from Macmillan Publishers Ltd: Leukemia, copyright 2011.